BPC-157 vs TB-500

The two most-sold 'healing peptides' — is there any human evidence for either?

No head-to-head trial — cross-trial comparison
In one paragraphNeither has a controlled human trial for the injuries they are sold for. BPC-157's entire human literature is one 12-patient case series and a two-person pilot; TB-500 has none by injection, though a pharmaceutical eye-drop form of its parent molecule reached phase 3 for dry eye and did not win approval. Both are grade D for healing, both are prohibited in sport at all times, and both are unapproved everywhere. The difference between them is which animal it was studied in.

Side by side

D BPC-157D TB-500
LYO grade (healing)DD
Controlled human trials for injury00
Best human evidence12-patient retrospective knee case series; 2-person IV pilotTwo phase 3 trials of a thymosin β4 eye drop (dry eye) — not injected TB-500
What it is15-amino-acid synthetic fragment of a gastric protein17-amino-acid fragment of thymosin β4, a natural actin-binding protein
Animal evidenceRat tendon, ligament, gut and vascular modelsMouse and rat wound, cardiac and corneal models
Systematic review2025: 544 articles screened, 36 included, 1 humanNone focused on TB-500
US compounding (2026)Committee recommended 8–6; not yet on the listCommittee recommended 8–6; not yet on the list
WADAProhibited (S0)Prohibited (S2.3)
Verdict

A tie at D. The honest comparison is not 'which works better' but 'which has been tested' — and for tendon, muscle or ligament injury in people, the answer for both is neither.

What exists in people

BPC-157: a 2025 systematic review searched from 1993 to 2024 and found one human study — a retrospective report of 12 patients with knee pain given intra-articular injections, with no control group. A separate 2025 pilot gave the peptide intravenously to two healthy volunteers. That is all.

TB-500: nothing by injection. The parent molecule, thymosin β4, was developed as an eye drop (RGN-259) and tested in two phase 3 dry-eye trials with mixed results and no approval. There is no human study of injected TB-500 for any musculoskeletal outcome.

Why the animal data is not enough

Rodent tendon and muscle heal differently from human tissue, doses scale poorly, and almost every animal study of both peptides comes from a small number of laboratories. Consistent animal results are the reason to run a human trial, not a substitute for one — and thirty years on, for BPC-157, no one has.

What is actually in the vial

Independent testing of research-market vials of both peptides has found wide variation between labelled and actual content, including vials with none of the named peptide. Because neither is manufactured to pharmaceutical standards anywhere, a claim about either is a claim about an unverified powder.

Questions people actually ask

Which is better for tendon injury, BPC-157 or TB-500?
There is no human evidence for either, so no answer. Both rest on rodent models.
Can they be combined?
They are sold in combination, but no human study has tested either alone for injury, let alone together.
Are they legal?
Both are unapproved in every jurisdiction LYO covers and banned in sport at all times. In the US an advisory committee voted in July 2026 to allow pharmacies to compound both; the FDA has not acted on it.

References

  1. 1
  2. 2
  3. 3